Categories Uncategorized

Researchers Find That Psychedelic Substance Effects Are Akin to Mystical Experiences

Researchers in Finland are looking into the relationship between mystical experiences and psychedelic substances. Their new research study shows that the use of the Finnish version of the MEQ30 assessment to capture the effects of psychedelic substances on different individuals records the personal experiences accurately.

Study author and postdoctoral researcher at Tampere University, Samuli Kangaslampi, stated that studies with both healthy volunteers and clinical populations and also population-based research, show that some individuals may undergo positive changes in their relationships as well as their well-being after the use of various psychedelic substances.

This is despite the lack of evidence to back these claims due to the lack of enough research from Nordic contexts as well as the limitation of mystical-type psychedelic induced experiences to only some cultural surroundings. The study shows that these positive changes may be as a result of mystical experiences that occur while under the influence of psychedelics.

The study, which examined 288 psychedelic users, all fluent in Finnish, used a Finnish translated version of the Mystical Experience Questionnaire (MEQ30) to validly and reliably measure their transcendent experiences. This questionnaire was originally created in English and was used to evaluate transcendental occurrences as well as the character of said distinct experience.

Kangaslampi and his colleagues discovered there was a higher probability that individuals who had high scores on the MEQ30 would describe the psychedelic occurrence as spiritual, mystical or religious and also as personally significant. The researchers noted that despite it being weak, the connection between the experience being sad, fun and or difficult was significant. Recent research has also demonstrated that going through a mystical occurrence may be connected to better relationships, both with oneself as well as others and the natural environment.

Psychedelics are known to give rise to strong personal experiences that are similar to those that have been described by dedicated mediators, antics and also religious practitioners. To understand this better, scientists are looking into various ways of evaluating these experiences on top of deducing their possible effects and meanings. This will open up an array of possibilities for researchers to delve deeper into the study of psychedelic substances as well as the effects they have on different individuals.

Additionally, Kangaslampi explained that while profound and powerful experiences were noted in many psychedelics consumers and that the goal of the study was to evaluate and prove mystical experiences, the discussion on whether the various attributes the experiences possess and how they are better described; be it as emotional breakthroughs, peak experiences or mystical-type experiences, is still up for debate.

It remains to be seen what psychedelics companies like Cybin Corp. think about the description of psychedelic experiences as being mystical in nature.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 months ago